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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to iron 
and contribution to normal formation of haemoglobin and red blood cells 
pursuant to Article 14 of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted pursuant to Article 14 
of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to iron and contribution to normal formation of haemoglobin and red blood cells. The food constituent, 
iron, which is the subject of the health claim, is sufficiently characterised. Contribution to normal formation of 
haemoglobin and red blood cells is a beneficial physiological effect for infants and young children. A claim on 
iron and contribution to normal formation of haemoglobin and red blood cells in the general population has 
already been assessed by the Panel with a favourable outcome. The Panel considers that the role of iron in normal 
formation of haemoglobin and red blood cells applies to all ages, including infants and young children (from 
birth to three years). The Panel concludes that a cause and effect relationship has been established between 
dietary intake of iron and contribution to normal formation of haemoglobin and red blood cells.  
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to iron and 
contribution to normal formation of haemoglobin and red blood cells. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is iron, which is an essential nutrient and is 
measurable in foods by established methods. The Panel considers that iron is sufficiently 
characterised. 
The claimed effect proposed by the applicant is “role in the blood formation process”. The target 
population proposed by the applicant is infants and young children from birth to three years of age. 
The Panel considers that contribution to normal formation of haemoglobin and red blood cells is a 
beneficial physiological effect for infants and young children. 
A claim on iron and contribution to normal formation of haemoglobin and red blood cells in the 
general population has already been assessed by the Panel with a favourable outcome. The conclusion 
of the Panel was based on the well-established role of iron in preventing iron deficiency anaemia in 
humans. 
The Panel considers that the role of iron in normal formation of haemoglobin and red blood cells 
applies to all ages, including infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between dietary intake 
of iron and contribution to normal formation of haemoglobin and red blood cells. 
The following wording reflects the scientific evidence: “Iron contributes to normal formation of 
haemoglobin and red blood cells”. 
The Panel considers that in order to bear the claim, follow-on formulae should comply with the 
criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally 
complete foods for special medical purposes intended for use by infants and nutritionally complete 
foods for special medical purposes other than those intended for use by infants should comply with 
the criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-
based foods for infants and young children should comply with the criteria of composition of these 
foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young 
children should provide at least 15 % of the reference values for nutrition labelling for foods intended 
for infants and young children as laid down in Directive 2006/125/EC. Such amounts can be easily 
consumed as part of a balanced diet. The target population is infants and children up to three years. 
No Tolerable Upper Intake Level has been set for iron in this age group. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of 
permitted claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 22/08/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 04/10/2013. 
 During its meeting on 11/12/2013, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to iron and 
contribution to normal formation of haemoglobin and red blood cells. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: iron and contribution to normal 
formation of haemoglobin and red blood cells. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of iron, a positive assessment of its safety, nor a decision on whether iron is, or is not, 
classified as a foodstuff. It should be noted that such an assessment is not foreseen in the framework 
of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9-31 Avenue des 
Nerviens, 1040 Brussels, Belgium. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is iron. 
Health relationship as claimed by the applicant 
According to the applicant, iron plays an important role in the blood formation process. Iron intake 
increases haemoglobin and serum ferritin concentrations depending on baseline haemoglobin levels.  
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “Iron is important for blood 
formation”. 
As equivalent alternative wordings, the applicant has also proposed: “iron contributes to/is involved 
in/is important for/plays an important role for/is necessary for/participates to/is needed for/supports 
the development of/the normal development of/the normal function of/the function of blood 
formation/blood/red blood cells/blood haematopoises/red blood cell formation/haemoglobin-
formation”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants and young children from birth to three 
years of age. The claim should be used on foods that are exclusively intended for the category of 
infants and young children, and in line with the composition laid down in the specific directives 
(Directive 2006/141/EC; Directive 2006/125/EC; Directive 1999/21/EC). 
According to the applicant, the quantity needed to achieve the claimed effect is: 
 For follow-on formulae, the content in iron should be within the range set in 
Directive 2006/141/EC. 
 For dietary foods for special medical purposes, the content in iron should be within the range 
set in Directive 1999/21/EC. 
 For processed cereal-based foods and baby foods, the content in iron should be within the 
range set in Directive 2006/125/EC. 
 For processed cereal-based foods and baby foods, the content in iron should reach at least 
15 % of the Nutrient Reference Values set in Directive 2006/125/EC, i.e. 15 % of 6 mg per 
100 g or 100 ml or per serving, as reconstituted. 
 For foods intended for infants and young children other than follow-on formulae, processed 
cereal-based foods and baby foods, the content in iron should reach at least 15 % of the 
Nutrient Reference Values set in Directive 2006/141/EC (replacing Directive 91/321/EC), i.e. 
15 % of 8 mg per 100 ml product ready for use. 
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ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claim is iron, which is an essential nutrient and is 
measurable in foods by established methods. 
Iron occurs naturally in foods in various forms, principally haem iron derived from haemoglobin and 
myoglobin in flesh foods, and non-haem iron in plant foods (IoM, 2001). Different forms of iron are 
authorised for addition to foods (Annex I of Regulation (EC) No 1925/2006
5
, Annex I of 
Directive 2002/46/EC
6
, Annex III of Directive 2006/141/EC
7





). This evaluation applies to iron naturally present in foods and those forms 
authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006, Annex II of 
Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of Directive 2006/125/EC, 
Directive 2001/15/EC). 
The Panel considers that the food constituent, iron, which is the subject of the health claim, is 
sufficiently characterised.  
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “role in the blood formation process”. The target 
population proposed by the applicant is infants and young children from birth to three years of age. 
The Panel considers that contribution to normal formation of haemoglobin and red blood cells is a 
beneficial physiological effect for infants and young children. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, Science Direct and Scopus using the 
following search terms: “blood formation”, “h*ematopoiesis”, “*h*em*”, “iron”, “ferritin”, “child*”, 
“follow-on formula”, “complementary feeding”, “weaning food”, “bioavailability”, “iron toxicity”, 
“iron overload”. The applicant selected English and German publications from 2000 to 2009 of 
human intervention studies, reviews and meta-analyses in infants and children up to five years old. 
The human intervention studies which were identified by the applicant as being pertinent to the health 
claim investigated the effect of iron supplementation or iron fortified formula/foods on plasma ferritin 
and haemoglobin in infants and young children (Singhal et al., 2000; Domellöf et al., 2001, 2002, 
2008; Bramhagen et al., 2003; Friel et al., 2003; Lozoff et al, 2003; Nagpal et al., 2004; Wall et al., 
2005; Ziegler et al., 2009). The applicant also identified two literature reviews as being pertinent to 
the health claim. The reviews describe randomised controlled trials investigating the effect of iron 
supplementation on prevention of iron deficiency and on haemoglobin concentrations in infants and 
young children (Iannotti et al., 2006; Gera et al., 2007). The applicant also provided in vitro and 
animal studies (Bouhallab et al., 2002; Etcheverry et al., 2004a, b; Kibangou et al., 2005; Rohner et 
                                                     
5 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
7 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33. 
8 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
9 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes 
in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25. 
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al., 2007), three extracts from textbooks in German and six reports/papers from scientific bodies as 
being pertinent to the health claim (IoM, 2001; Aggett et al., 2002; INACG, 2002; JHCI, 2003; 
FAO/WHO, 2004; DGE, 2008). 
Iron is an essential trace element that is mainly present in erythrocytes as haemoglobin, which 
transports oxygen to tissues (Hunt, 2005).  
The Panel has already assessed a claim on iron and contribution to normal formation of haemoglobin 
and red blood cells with a favourable outcome (EFSA NDA Panel, 2009). The target population was 
the general population.  
The conclusion of the Panel was based on the well-established role of iron in preventing iron 
deficiency anaemia in humans (IoM, 2001; FAO/WHO, 2004). 
The Panel considers that the role of iron in normal formation of haemoglobin and red blood cells 
applies to all ages, including infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between dietary intake 
of iron and contribution to normal formation of haemoglobin and red blood cells. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “Iron contributes to 
normal formation of haemoglobin and red blood cells”. 
5. Conditions and restrictions of use  
The Panel considers that in order to bear the claim: 
 follow-on formulae should comply with the criteria of composition of follow-on formulae as 
laid down in Directive 2006/141/EC; 
 nutritionally complete foods for special medical purposes intended for use by infants and 
nutritionally complete foods for special medical purposes other than those intended for use by 




 processed cereal-based foods for infants and young children should comply with the criteria 
of composition of these foods as laid down in Directive 2006/125/EC; 
 other foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for nutrition labelling for foods intended for infants and young children as 
laid down in Directive 2006/141/EC.  
Such amounts can be easily consumed as part of a balanced diet. The target population is infants and 
children up to three years. No Tolerable Upper Intake Level has been set for iron (EFSA, 2004). 
 
                                                     
10 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, 
p. 29–36. 
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CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, iron, which is the subject of the health claim, is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “role in the blood formation process”. The 
target population proposed by the applicant is infants and young children from birth to three 
years of age. Contribution to normal formation of haemoglobin and red blood cells is a 
beneficial physiological effect for infants and young children. 
 A cause and effect relationship has been established between dietary intake of iron and 
contribution to normal formation of haemoglobin and red blood cells. 
 The following wording reflects the scientific evidence: “Iron contributes to normal formation 
of haemoglobin and red blood cells”. 
 In order to bear the claim, follow-on formulae should comply with the criteria of composition 
of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods 
for special medical purposes intended for use by infants and nutritionally complete foods for 
special medical purposes other than those intended for use by infants should comply with the 
criteria of composition of these foods as laid down in Directive 1999/21/EC; processed 
cereal-based foods for infants and young children should comply with the criteria of 
composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended 
for infants and young children should provide at least 15 % of the reference values for 
nutrition labelling for foods intended for infants and young children as laid down in 
Directive 2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The 
target population is infants and children up to three years. No Tolerable Upper Intake Level 
has been set for iron in this age group. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on iron and contribution to normal formation of haemoglobin and red blood 
cells pursuant to Article 14 of Regulation (EC) No 1924/2006 (Claim serial No: 0067_FR). February 
2008. Submitted by Specialised Nutrition Europe (formerly IDACE). 
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